We are live on ! Find out more
FCMI

Foresite Capital Management III Portfolio holdings

AUM $37.9M
1-Year Est. Return 6.87%
This Fund
S&P 500
This Quarter Est. Return
+22.47%
1 Year Est. Return
-6.87%
3 Year Est. Return
+444.07%
5 Year Est. Return
+547.28%
10 Year Est. Return
–
AUM
$363M
AUM Growth
+$56.9M
Cap. Flow
+$26.1M
Cap. Flow %
7.19%
Top 10 Hldgs %
84.78%
Holding
30
New
4
Increased
7
Reduced
6
Closed
10

Top Buys

Rank Stock Value
1
AKAO
Achaogen Inc
AKAO
+$12.6M
2
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$9.41M
3
XLRN
Acceleron Pharma
XLRN
+$8.99M
4
ALDR
Alder Biopharmaceuticals
ALDR
+$7.98M
5
ASND icon
Ascendis Pharma A/S
ASND
+$7.54M

Top Sells

Rank Stock Value
1
KYNB
Kyntra Bio
KYNB
+$8.07M
2
FBRX icon
Forte Biosciences
FBRX
+$5.46M
3
BLCM
Bellicum Pharmaceuticals, Inc.
BLCM
+$5.29M
4
LOXO
Loxo Oncology, Inc
LOXO
+$4.86M
5
DERM
Dermira, Inc.
DERM
+$3.48M

Sector Composition

Rank Sector Weight
1 Healthcare 49.78%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NSTG
26
DELISTED
NanoString Technologies, Inc.
NSTG
– –
-178,681
Closed -$2.96M
INFI
27
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
– –
-738,896
Closed -$1.16M
BLCM
28
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
– –
-45,273
Closed -$5.29M
OREX
29
DELISTED
Orexigen Therapeutics, Inc.
OREX
– –
-380,530
Closed -$1.1M
BHVN
30
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
– –
-30,000
Closed -$750K
1
2

Similar funds

PIM
Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return
KCGDR
Kiron Capital Gestao de Recursos Sao Paulo, Brazil $36.9M AUM 49.85% 1-Year Est. Return
SEM
Spectrum Equity Management San Francisco, California $39.1M AUM 63.69% 1-Year Est. Return
ALFIA
Accel Leaders Fund II Associates Palo Alto, California $36.6M AUM 58.14% 1-Year Est. Return
MCMI
Matrix China Management III Grand Cayman, Cayman Islands $39.3M AUM
LCM
LH Capital Markets New York $39.4M AUM 14.61% 1-Year Est. Return
HLC
Hunt Lane Capital New York $39.6M AUM 58.74% 1-Year Est. Return
KXA
KPCB XV Associates Menlo Park, California $35.8M AUM 57.59% 1-Year Est. Return

Foresite Capital Management III's Q3 2017 Portfolio in Review

As of Q3 2017, Foresite Capital Management III held 30 positions worth $363M, up 19% from $306M the previous quarter. Its ten largest holdings account for 85% of the portfolio.

Foresite Capital Management III deployed $26.1M of net new capital in Q3 2017, opening 4 new positions and adding to 7 existing holdings. Its largest new stake was MyoKardia, Inc. Common Stock: 295,000 shares worth $12.6M.

By sector, the portfolio is most concentrated in Healthcare at 50% of assets, up from 44% a quarter earlier.

On the sell side, the largest reduction was Forte Biosciences, an estimated $5.46M trimmed.

  • Foresite Capital Management III's largest Q3 2017 buy was MyoKardia, Inc. Common Stock: 295,000 shares worth $12.6M.
  • Foresite Capital Management III added most to Achaogen Inc in Q3 2017, an estimated $12.6M increase.
  • Foresite Capital Management III's biggest Q3 2017 reduction was Forte Biosciences, cutting an estimated $5.46M.
  • Foresite Capital Management III fully exited Kyntra Bio in Q3 2017, selling an estimated $8.07M.
  • Foresite Capital Management III's ten largest holdings make up 85% of its $363M portfolio in Q3 2017.
  • Foresite Capital Management III opened 4 new positions and closed 10 in Q3 2017.
  • Foresite Capital Management III's portfolio value rose 19% quarter-over-quarter to $363M.

Based on Foresite Capital Management III's 13F filing for Q3 2017, filed 13 Nov 2017.